Trexquant Investment LP Sells 157,097 Shares of Urogen Pharma $URGN

Trexquant Investment LP cut its stake in shares of Urogen Pharma (NASDAQ:URGN) by 91.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,454 shares of the company’s stock after selling 157,097 shares during the period. Trexquant Investment LP’s holdings in Urogen Pharma were worth $171,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in URGN. The Manufacturers Life Insurance Company raised its stake in shares of Urogen Pharma by 178.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 37,486 shares of the company’s stock worth $399,000 after purchasing an additional 24,006 shares during the period. Northern Trust Corp boosted its position in shares of Urogen Pharma by 8.1% during the 4th quarter. Northern Trust Corp now owns 310,074 shares of the company’s stock valued at $3,302,000 after acquiring an additional 23,345 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of Urogen Pharma by 9.3% during the 4th quarter. Ameriprise Financial Inc. now owns 49,153 shares of the company’s stock valued at $523,000 after acquiring an additional 4,188 shares during the last quarter. Bank of America Corp DE lifted its position in Urogen Pharma by 9.0% in the 4th quarter. Bank of America Corp DE now owns 72,472 shares of the company’s stock worth $772,000 after buying an additional 5,983 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in Urogen Pharma by 61.6% in the 4th quarter. Deutsche Bank AG now owns 31,263 shares of the company’s stock worth $333,000 after buying an additional 11,916 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors.

Insider Activity at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 1,520 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $19.11, for a total value of $29,047.20. Following the completion of the sale, the general counsel directly owned 43,305 shares of the company’s stock, valued at $827,558.55. This trade represents a 3.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the sale, the insider directly owned 148,229 shares of the company’s stock, valued at $2,622,171.01. The trade was a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 25,062 shares of company stock valued at $465,115 over the last ninety days. Corporate insiders own 4.70% of the company’s stock.

Urogen Pharma Trading Down 7.6%

NASDAQ:URGN opened at $19.11 on Thursday. The stock has a market capitalization of $884.03 million, a P/E ratio of -5.76 and a beta of 1.10. The stock has a 50-day moving average price of $17.97 and a 200 day moving average price of $12.72. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $21.71.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $24.22 million for the quarter, compared to analysts’ expectations of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. On average, research analysts predict that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Scotiabank reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Friday, June 13th. Guggenheim reaffirmed a “buy” rating and issued a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a “buy” rating in a research note on Friday, June 13th. Piper Sandler started coverage on Urogen Pharma in a research note on Monday, August 18th. They issued an “overweight” rating and a $36.00 target price on the stock. Finally, HC Wainwright lowered their price target on Urogen Pharma from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Urogen Pharma has an average rating of “Buy” and an average price target of $32.00.

Urogen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.